Exercise induced bronchospasm (EIB) affects approximately 10% of normal individuals with higher prevalence rates among children, obese adults, and competitive athletes. Although hyperpnea with dry air is the best known cause, the problem is multifactorial with atopy, asthma and chlorine all playing
Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD.